Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOMA vs CYCLOBENZAPRINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Centrally acting muscle relaxant; acts at brainstem reticular formation and spinal cord levels to inhibit polysynaptic reflexes, possibly via GABAergic and monoaminergic pathways.
Cyclobenzaprine is a centrally acting muscle relaxant that reduces tonic somatic motor activity at the supraspinal level, primarily at the brainstem reticular formation and descending pathways. It is structurally related to tricyclic antidepressants and inhibits reuptake of norepinephrine and serotonin, but the direct relationship to its muscle relaxant effects is not fully established.
Acute musculoskeletal pain (FDA-approved),Off-label: chronic low back pain, muscle spasms associated with neurological disorders
Treatment of muscle spasm associated with acute, painful musculoskeletal conditions (FDA approved),Adjunct to rest and physical therapy for relief of muscle spasm (FDA approved)
250 mg to 350 mg orally three times daily and at bedtime.
Adults: 5 mg orally three times daily; may increase to 10 mg three times daily based on response. Maximum 30 mg per day.
1-2 hours; prolonged to 3-4 hours in hepatic impairment; parent drug rapidly cleared via CYP2C19 metabolism to meprobamate (active, t1/2 6-16 hours).
Terminal half-life: 18–24 hours (range 8–37 hours). Clinical context: requires multiple doses to achieve steady state (5–6 days); active metabolite norcyclobenzaprine has half-life ~30 hours.
Hepatic via CYP2C19 and CYP3A4; also undergoes dealkylation and hydroxylation.
Hepatic metabolism primarily via CYP3A4, CYP1A2, and CYP2D6; also undergoes N-demethylation and glucuronidation. Active metabolites include norcyclobenzaprine.
Renal: ~60-70% as metabolites (including meprobamate and glucuronide conjugates); fecal: minimal; biliary: negligible.
Renal: ~50% as unchanged drug and metabolites; Fecal: ~40% primarily as metabolites; Biliary: minimal.
~60% bound to albumin.
~93% bound to albumin and alpha-1-acid glycoprotein.
0.7-1.0 L/kg; consistent with moderate tissue distribution.
~5 L/kg (range 3–7 L/kg). Clinical meaning: extensive tissue distribution, including central nervous system.
Oral: ~100% (rapidly and completely absorbed).
Oral: 33–55% due to first-pass metabolism; lower for immediate-release compared to extended-release (same extent but slower absorption).
No specific dose adjustment guidelines; use with caution in severe renal impairment (GFR <30 m L/min).
No specific dosing adjustment recommended; use caution in severe renal impairment due to potential accumulation.
Contraindicated in severe hepatic impairment (Child-Pugh class C). Use with caution in mild to moderate impairment; reduce dose or extend dosing interval.
Child-Pugh Class A or B: No adjustment. Child-Pugh Class C: Contraindicated due to risk of toxicity (minimal data). Use with caution in mild to moderate impairment; consider lower starting dose.
Not recommended for children under 12 years of age. For adolescents, adult dosing may be considered based on weight and clinical judgment.
Not recommended for children under 15 years; safety and efficacy not established. For adolescents ≥15 years: same as adult dosing.
Initiate at lower doses (e.g., 250 mg three times daily) due to increased sensitivity and risk of CNS adverse effects; monitor renal function.
Start with 5 mg once daily; increase slowly to a maximum of 10 mg three times daily over 2 weeks. Increased sensitivity; monitor for anticholinergic effects and sedation.
None
None
May cause sedation, dizziness, and impaired psychomotor function; avoid driving or operating machinery.,Risk of abuse, dependence, and withdrawal; use with caution in patients with substance use disorder.,Concomitant use with alcohol or other CNS depressants may potentiate effects.,Elderly patients more sensitive to anticholinergic effects; monitor for confusion or falls.,Hepatic impairment: reduce dose or avoid use.,Pregnancy: limited data; use only if clearly needed.
Serotonin syndrome risk, especially with concomitant serotonergic drugs (e.g., SSRIs, SNRIs, MAOIs),Sedation and impairment of motor skills; caution with driving or operating machinery,Anticholinergic effects (e.g., urinary retention, angle-closure glaucoma, constipation),Cardiovascular effects: tachycardia, QT prolongation, arrhythmias (especially in elderly or with pre-existing heart disease),Hepatic impairment: use with caution; reduced clearance in mild impairment, avoid in severe impairment,Withdrawal symptoms after abrupt discontinuation: dysphoria, anxiety, insomnia,Elderly patients: increased risk of falls, confusion, anticholinergic toxicity
Hypersensitivity to carisoprodol or its components,Acute intermittent porphyria,Concurrent use with other CNS depressants (relative)
Hypersensitivity to cyclobenzaprine or any component of the formulation,Concomitant use or within 14 days of MAO inhibitors (hypertensive crisis risk),Acute recovery phase after myocardial infarction,Arrhythmias, heart block, or conduction disturbances,Hyperthyroidism,Severe hepatic impairment
No specific food interactions reported. Avoid alcohol and grapefruit juice as they may enhance sedative effects.
Alcohol should be avoided due to additive CNS depression. Grapefruit juice may increase cyclobenzaprine levels (though data is limited, caution is advised). High-fat meals may delay absorption but not clinically significant. No specific dietary restrictions are required.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal resorptions and skeletal anomalies. Second/third trimester: Risk of neonatal withdrawal syndrome (irritability, hypertonia) with chronic maternal use near term.
Cyclobenzaprine is classified as FDA Pregnancy Category B. Animal reproduction studies have not shown fetal risk, and there are no adequate and well-controlled studies in pregnant women. Risk cannot be ruled out. First trimester: Limited human data, but no structural anomalies reported. Second trimester: No specific adverse effects documented. Third trimester: Potential for neonatal withdrawal symptoms (e.g., jitteriness, respiratory depression) if used near term.
M/P ratio unknown. Carisoprodol and its active metabolite meprobamate are excreted in breast milk. Potential for sedation in nursing infants. Use caution; monitor infant for drowsiness and feeding difficulties.
Cyclobenzaprine is excreted into breast milk in low amounts; the M/P ratio is unknown. Due to its anticholinergic effects, there is potential for adverse effects in the nursing infant (e.g., sedation, constipation). The American Academy of Pediatrics considers it compatible with breastfeeding, but caution is advised; alternatives may be preferred.
No pharmacokinetic studies in pregnancy. Use lowest effective dose for shortest duration; avoid chronic use due to risk of dependence and neonatal withdrawal.
No specific dose adjustments are recommended during pregnancy. Pharmacokinetic parameters (e.g., clearance) are not significantly altered by pregnancy. Use the lowest effective dose for the shortest duration due to lack of safety data.
SOMA (carisoprodol) is a centrally acting skeletal muscle relaxant metabolized to meprobamate, a controlled substance with abuse potential. Avoid in patients with porphyria. Use lowest effective dose for shortest duration (max 2-3 weeks). Monitor for sedation and dizziness, especially when combined with other CNS depressants. Taper to avoid withdrawal if used long-term.
Cyclobenzaprine is structurally related to tricyclic antidepressants and shares similar anticholinergic and sedative properties. Onset of action for muscle relaxation is typically 1 hour, but maximal effect may take several days. Avoid use in patients with hyperthyroidism, cardiac disease, or those on MAOIs. Not recommended for use longer than 2-3 weeks due to lack of evidence for chronic use. Caution in elderly due to anticholinergic effects and fall risk.
Avoid driving or operating machinery until you know how SOMA affects you, as it may cause drowsiness or dizziness.,Do not consume alcohol or other CNS depressants (e.g., benzodiazepines, opioids) while taking SOMA.,Take exactly as prescribed; do not increase dose or duration due to risk of dependence and withdrawal.,Store securely to prevent misuse; dispose of unused medication properly.,Contact your doctor if you experience severe drowsiness, confusion, or signs of allergic reaction.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Do not drink alcohol or use other CNS depressants (e.g., benzodiazepines, opioids) while taking this medication, as it may increase sedation.,Take this medication exactly as prescribed, usually 3 times a day. Do not take more or less than directed.,This medication is intended for short-term use (up to 2-3 weeks) for muscle spasm. Do not use it for longer without consulting your doctor.,If you experience dry mouth, try sucking on sugar-free candy or ice chips. If you have difficulty urinating or vision changes, contact your doctor.,Do not stop taking this medication abruptly without consulting your doctor, although withdrawal is uncommon with short-term use.
"Somatostatin, a potent inhibitor of growth hormone and insulin secretion, may antagonize the effects of methohexital, a barbiturate anesthetic, by altering glucose metabolism and hemodynamic stability. This interaction can lead to reduced efficacy of methohexital, requiring higher doses for induction of anesthesia, and may increase the risk of prolonged recovery or adverse cardiovascular events. Clinically, patients may experience unpredictable depth of anesthesia or delayed emergence."
"Concurrent administration of somatostatin and pentobarbital may lead to enhanced CNS depression and increased risk of hypotension. Somatostatin inhibits the release of several hormones and can potentiate the sedative effects of pentobarbital through additive central nervous system depression. Clinically, this interaction may result in excessive sedation, respiratory depression, and cardiovascular instability, particularly in elderly or debilitated patients."
"Somatostatin inhibits the release of growth hormone and various gastrointestinal hormones, leading to reduced hepatic blood flow and decreased metabolic clearance of coadministered drugs. Thiopental undergoes extensive hepatic metabolism and its clearance may be impaired by somatostatin-induced reduction in hepatic perfusion, potentially resulting in prolonged anesthesia and increased risk of respiratory depression or hypotension. Additionally, somatostatin may directly enhance the central nervous system depressant effects of thiopental, although the clinical significance of this interaction is variable."
"The combination of cyclobenzaprine and carbinoxamine results in additive central nervous system depression due to their shared anticholinergic and sedative properties. This can lead to excessive sedation, impaired cognitive and motor function, and increased risk of falls or accidents. Severe cases may result in respiratory depression, especially in elderly patients or those with preexisting conditions."
"Cyclobenzaprine, a centrally acting muscle relaxant with tricyclic antidepressant (TCA)-like structure, and Dezocine, an opioid partial agonist analgesic with mu-opioid receptor activity, both depress the central nervous system (CNS) and have additive serotonergic effects. Concomitant use increases the risk of excessive CNS depression, manifesting as sedation, respiratory depression, and impaired psychomotor function, as well as potential serotonin syndrome due to combined serotonergic activity. Clinically, patients may experience profound drowsiness, confusion, respiratory compromise, and in severe cases, coma or death from respiratory failure."
"Lumacaftor, a potent inducer of cytochrome P450 (CYP) 3A4, significantly reduces the systemic exposure of cyclobenzaprine, a CYP3A4 substrate. This results in decreased plasma concentrations of cyclobenzaprine, potentially leading to reduced therapeutic efficacy for muscle spasm relief. Patients may require dose adjustments or alternative therapies to maintain clinical benefit."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOMA vs CYCLOBENZAPRINE HYDROCHLORIDE, answered by our medical review team.
SOMA is a Skeletal Muscle Relaxant that works by Centrally acting muscle relaxant; acts at brainstem reticular formation and spinal cord levels to inhibit polysynaptic reflexes, possibly via GABAergic and monoaminergic pathways.. CYCLOBENZAPRINE HYDROCHLORIDE is a Skeletal Muscle Relaxant that works by Cyclobenzaprine is a centrally acting muscle relaxant that reduces tonic somatic motor activity at the supraspinal level, primarily at the brainstem reticular formation and descending pathways. It is structurally related to tricyclic antidepressants and inhibits reuptake of norepinephrine and serotonin, but the direct relationship to its muscle relaxant effects is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOMA and CYCLOBENZAPRINE HYDROCHLORIDE depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOMA is: 250 mg to 350 mg orally three times daily and at bedtime.. The standard adult dose of CYCLOBENZAPRINE HYDROCHLORIDE is: Adults: 5 mg orally three times daily; may increase to 10 mg three times daily based on response. Maximum 30 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOMA and CYCLOBENZAPRINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOMA is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal resorptions and skeletal anomalies. Second/third trimester: Risk of neonatal with. CYCLOBENZAPRINE HYDROCHLORIDE is classified as Category A/B. Cyclobenzaprine is classified as FDA Pregnancy Category B. Animal reproduction studies have not shown fetal risk, and there are no adequate and well-controlled studies in pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.